Benralizumab
- Generic Name
- Benralizumab
- Brand Names
- Fasenra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1044511-01-4
- Unique Ingredient Identifier
- 71492GE1FX
- Background
Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transd...
- Indication
Benralizumab is indicated as a maintenance treatment of patients 12 years or older with severe asthma and an eosinophilic phenotype. The pathology of severe asthma with eosinophilic phenotype is also denotated as TH2-high phenotype. The patients with this phenotype are characterized by the expression of IL-5 and IL-13, airway hyperresponsiveness, responsiven...
- Associated Conditions
- Severe Eosinophilic Asthma
- Associated Therapies
- -
Effect of Benralizumab in Atopic Dermatitis
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 20
- Registration Number
- NCT03563066
- Locations
- 🇨🇦
McMaster Cardio-Respiratory Research Lab, Hamilton, Ontario, Canada
Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis
- Conditions
- Interventions
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 33
- Registration Number
- NCT03450083
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
The Effect of Benralizumab on Exercise-induced Bronchoconstriction
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Louis-Philippe Boulet
- Target Recruit Count
- 40
- Registration Number
- NCT03327701
Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 10
- Registration Number
- NCT03010436
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 233
- Registration Number
- NCT02869438
- Locations
- 🇵🇭
Research Site, Quezon City, Philippines
Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma
- Conditions
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 103
- Registration Number
- NCT02814643
- Locations
- 🇺🇸
Research Site, Clinton, Utah, United States
Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis
- Conditions
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT02772419
Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2022-02-08
- Target Recruit Count
- 20
- Registration Number
- NCT02130882
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.